Health-related quality of life in primary hepatic cancer: a systematic review assessing the methodological properties of instruments and a meta-analysis comparing …
K Wohlleber, P Heger, P Probst, C Engel… - Quality of Life …, 2021 - Springer
Purpose Patient-reported outcomes including health-related quality of life (HRQoL) are
important oncological outcome measures. The validation of HRQoL instruments for patients …
important oncological outcome measures. The validation of HRQoL instruments for patients …
Sorafenib plus octreotide is an effective and safe treatment in advanced hepatocellular carcinoma: multicenter phase II So. LAR. study
SD Prete, L Montella, M Caraglia, L Maiorino… - Cancer chemotherapy …, 2010 - Springer
Purpose Advanced hepatocellular carcinoma (HCC) not eligible for local therapies has
limited chances of cure. Sorafenib is a multikinase inhibitor with proven activity in advanced …
limited chances of cure. Sorafenib is a multikinase inhibitor with proven activity in advanced …
Somatostatin and CXCR4 chemokine receptor expression in hepatocellular and cholangiocellular carcinomas: tumor capillaries as promising targets
D Kaemmerer, R Schindler, F Mußbach, U Dahmen… - BMC cancer, 2017 - Springer
Background Hepatocellular (HCC) and cholangiocellular carcinomas (CCC) display an
exceptionally poor prognosis. Especially for advanced disease no efficient standard therapy …
exceptionally poor prognosis. Especially for advanced disease no efficient standard therapy …
Approach to the patient with pseudoacromegaly
P Marques, M Korbonits - The Journal of Clinical Endocrinology …, 2022 - academic.oup.com
Pseudoacromegaly encompasses a heterogeneous group of conditions in which patients
have clinical features of acromegaly or gigantism, but no excess of GH or IGF-1 …
have clinical features of acromegaly or gigantism, but no excess of GH or IGF-1 …
Associations of lifestyle and dietary habits with hyperlipidemia in Lebanon
Aim: This study was designed to evaluate the effects of dietary and lifestyle habits on several
blood lipid parameters in the Lebanese population. Methods: This was a cross-sectional …
blood lipid parameters in the Lebanese population. Methods: This was a cross-sectional …
[HTML][HTML] Somatostatin receptor subtypes 2 and 5 are associated with better survival in operable hepatitis B‑related hepatocellular carcinoma following octreotide long …
Y Liu, L Jiang, Y Mu - Oncology letters, 2013 - spandidos-publications.com
Liver resections for hepatocellular carcinoma (HCC) in cirrhotic livers are associated with
early recurrence and poor survival. Somatostatin analogues (SSAs) have been reported to …
early recurrence and poor survival. Somatostatin analogues (SSAs) have been reported to …
Impact of different anticancer regimens on biomarkers of angiogenesis in patients with advanced hepatocellular cancer
G Treiber, T Wex, P Malfertheiner - Journal of cancer research and clinical …, 2009 - Springer
Objective Advanced hepatocellular cancer (HCC) is a highly vascularised tumor with limited
treament options. We wanted to evaluate the impact of different treatments on systemic …
treament options. We wanted to evaluate the impact of different treatments on systemic …
[PDF][PDF] Somatostatin in hepatocellular carcinoma: experimental and therapeutic implications
E Kouroumalis, D Samonakis, G Notas - Hepatoma Research, 2018 - f.oaes.cc
The neuropeptide somatostatin has been shown to control the secretion of several
hormones and growth factors, but also to inhibit the proliferation of several tumor cells …
hormones and growth factors, but also to inhibit the proliferation of several tumor cells …
Octreotide and hepatocellular carcinoma
F Farinati, A Sergio, A Baldan, P Zucchetta… - British journal of …, 2007 - nature.com
The treatment of advanced hepatocellular carcinoma (HCC) in patients no longer eligible for
surgical, percutaneous or transarterial therapies is dismal. Chemotherapy, anti-estrogens or …
surgical, percutaneous or transarterial therapies is dismal. Chemotherapy, anti-estrogens or …
Expression of oestrogen and growth factor receptors in hepatocellular carcinoma
J Meza-Junco, AJ Montano-Loza… - Clinical …, 2007 - clinicaloncologyonline.net
1 Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003;
9: 669e676. 2Giantonio BJ, Catalano PJ, Meropol NJ, et al. High-dose bevacizumab in …
9: 669e676. 2Giantonio BJ, Catalano PJ, Meropol NJ, et al. High-dose bevacizumab in …